Anika Therapeutics (ANIK) Leases (2016 - 2025)
Anika Therapeutics (ANIK) has disclosed Leases for 13 consecutive years, with $25.9 million as the latest value for Q4 2025.
- On a quarterly basis, Leases rose 0.99% to $25.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.9 million, a 0.99% increase, with the full-year FY2025 number at $25.9 million, up 0.99% from a year prior.
- Leases was $25.9 million for Q4 2025 at Anika Therapeutics, up from $24.2 million in the prior quarter.
- In the past five years, Leases ranged from a high of $31.6 million in Q2 2022 to a low of $20.5 million in Q1 2022.
- A 5-year average of $26.3 million and a median of $26.6 million in 2024 define the central range for Leases.
- Peak YoY movement for Leases: soared 47.07% in 2023, then fell 10.96% in 2025.
- Anika Therapeutics' Leases stood at $21.0 million in 2021, then surged by 46.47% to $30.7 million in 2022, then dropped by 10.24% to $27.6 million in 2023, then dropped by 6.78% to $25.7 million in 2024, then increased by 0.99% to $25.9 million in 2025.
- Per Business Quant, the three most recent readings for ANIK's Leases are $25.9 million (Q4 2025), $24.2 million (Q3 2025), and $24.7 million (Q2 2025).